FiercePharmaOriginal article
{"a":[{"_":"Alembic site slapped with FDA warning letter over patient consent concerns","$":{"href":"/pharma/alembic-bioequivalence-site-slapped-fda-warning-letter-over-informed-consent-concerns","hreflang":"en"}}]}
RegulatoryNegative
AI Analysis
Summary
Alembic Pharmaceuticals received an FDA warning letter following an inspection that identified patient consent concerns at one of its sites. The warning letter represents an escalation from the initial Form 483 issued during the inspection earlier in 2026.
Outcome Details
FDA warning letter issued following inspection that yielded Form 483 for patient consent concerns
Importance:6/10
Sentiment:
-0.80
FDA warning letterregulatory actionpatient consentgenericscompliance
Read the original article
Published by FiercePharma on July 21, 2026 11:29 AM